NeuroFerro Ferroptosis Inhibitors For Neurodegenerative Disorders
- Coordinator
- Universiteit Antwerpen, Belgium
- Runs
- 1 October 2022 to 31 March 2025
- Status
- Running
- EU funding
- €240k
- Total cost
- —
- Partners
- 2 organisations in 2 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101065370
What the project is doing
In the project's own words, from its summary on CORDIS.
FERROptosis inhibitors for NEUROdegenerative disorders (NeuroFerro) will focus on the development of potent compounds with improved pharmacokinetic properties, including blood-brain barrier (BBB) permeability for future application in the treatment of neurodegenerative disorders. Ferroptosis is non-apoptotic programmed cell death that has been linked to the pathophysiological processes of many diseases, including dementia, Huntingtons disease, Alzheimers disease, Parkinsons disease and amyotrophic lateral sclerosis (ALS).
Neurological disorders are one of the most significant causes of disability-adjusted life-years and death worldwide with very limited treatment available. Although ferroptosis inhibitors developed by Augustyns and Vanden Berghe (supervisors) are currently best in class compounds, they suffer from no or minor BBB permeability. Therefore the main aim of the project will be the design and synthesis of novel ferroptosis inhibitors with improved pharmacokinetic parameters and high blood-brain barrier permeability to target ferroptosis in neurodegenerative disorders.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universiteit Antwerpen | Antwerpen | Belgium | Coordinator |
| Ryvu Therapeutics S.A. | Kraków | Poland | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI